Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome (II) + oxaliplatin + S-1 for first-line unresectable locally advanced or metastatic pancreatic cancer
ChiCTR2500098261Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan liposome, oxaliplatin and tegafur in pancreatic cancer (PC), sponsored by Changzhou First People's Hospital. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomeoxaliplatintegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500098261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098261.